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To the Editor:
Classical Hodgkin Lymphoma (cHL) is a B cell-derived
lymphoid malignancy, affecting 2.5–3/100,000 people per
year. To date, in patients diagnosed with advanced cHL no
reliable tool is able to—a priori—distinguish the subset of
patients at high risk for relapse or refractory disease. Clin-
ical risk indices for cHL, such as the International Prog-
nostic Score (IPS), have not been successfully applied as a
treatment decision tool in advanced stage cHL [1]. In this
study we show, that a previously published gene
expression-based predictor in advanced stage cHL patients
treated with ABVD [2] does not prove prognostic in 401
BEACOPP-treated advanced stage cHL patients. Using
transcriptome profiling, we identified however that three
individual genes, PDGFRA, TNFRSF8 (encoding CD30)
and CCL17 (encoding TARC), were significantly associated
with progression-free survival (PFS) after multiple test
correction in the BEACOPP-treated cohort, highlighting the
potential of a modified gene expression profiling approach
for pre-treatment risk assessment.
In search of a predictive tool in advanced stage cHL
patients, we have applied the previously published 23-gene
gene expression‐based predictor [2], that is prognostic for
overall survival (OS) in patients with locally extensive and
advanced stage disease treated with ABVD chemotherapy
in a distinct cohort of patients with advanced-stage cHL
patients treated with BEACOPP-based regimens. In parti-
cular, we explored the relationship of the predictor score
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with clinical parameters and OS and PFS in the BEACOPP-
based study cohort. For that purpose, we extracted RNA
from formalin‐fixed paraffin‐embedded (FFPE) diagnostic
biopsies of 404 patients with advanced stage cHL treated
within the HD12 and HD15 trials of the German Hodgkin
Study Group [3, 4]. Three samples were flagged as low
quality and removed from subsequent analysis. Inclusion
criteria were the documentation of a reference histology
result, the availability of an FFPE lymph-node specimen
obtained at first diagnosis, and a complete documentation of
present prognostic factors [3, 4]. To increase statistical
power for observations linked to treatment outcome, the
patient cohort was enriched for progression, relapse or death
events at a ratio of 1:2. Patient characteristics of the 401
patients are displayed in Table 1A. A majority of this cohort
has been previously utilized for an a priori risk assessment
by whole-slide image analysis [5].
We performed gene expression profiling of the under-
lying 404 samples using the NanoString nCounter platform.
As a quality control measurement, we performed an inter-
laboratory comparison of 24 randomly selected nCounter
gene expression measurements from our cohort and further
24 samples from the initial study [2] (Supplementary
Fig. 1). Samples were processed at two sites independently
(Vancouver, Canada; Kiel, Germany) as described pre-
viously [2] (see also Supplementary methods). We observed
an agreement between data generated at both institutions of
R2= 0.91 (Supplementary Fig. 2). The concordance of the
published 23-gene outcome predictor scores between the
two data sets was similar (R2= 0.90, Supplementary Fig. 3,
left panel). To further improve the transferability of the 23-
gene predictor, we recalibrated its weights (see Supple-
mentary methods). Here, we followed a previously pub-
lished strategy6, and re-adjusted the signature weights such
that the influence of data normalization on predictions is
Table 1 Patient characteristics of 401 advanced stage cHL patients
treated within clinical trials HD12 and HD15 and prediction analysis
of the adjusted gene predictor.
A. Patient characteristics with risk groups resulting from the adjusted gene
predictor
All High risk Low risk
N= 401 N= 149 N= 252
N % N % N %
Age (years)
Median 33 39 29
Range 18–60 18–60 18–59
18–45 317 79.1 103 69.1 214 84.9
45–60 84 20.9 46 30.9 38 15.1
Sex
Female 153 38.2 38 25.5 115 45.6
Male 248 61.8 111 74.5 137 54.4
cHL Subtype
Mixed cellularity 116 28.9 65 43.6 51 20.2
Nodular sclerosis 257 64.1 74 49.7 183 72.6
Lymphocyte-rich 11 2.7 3 2 8 3.2
Lymphocyte-depleted 4 1 3 2 1 0.4
cHL NOS 13 3.2 4 2.7 9 3.6
IPS (grouped)
0–1 114 28.4 29 19.5 85 33.7
2–3 224 55.9 92 61.7 132 52.4
4–7 63 15.7 28 18.8 35 13.9
Relapse/Death
None 232 57.9 81 54.4 151 59.9
Progression/Relapse only 79 19.7 30 20.1 49 19.4
Death only 54 13.5 29 19.5 25 9.9
Both 36 9 9 6 27 10.7
B. Overall survival (OS)
Variable univar. P multivar. P
Age <0.0001 <0.0001
Sex (male) 0.0513 0.1759
adj. gene predictor 0.0079 0.525
C. Progression-free survival (PFS)
Variable univar. P multivar. P
Age 0.0002 0.0006
Sex (male) 0.0014 0.0034
adj. gene predictor 0.1452 0.7881
D. OS and PFS with IPS
Variable OS PFS
multivar. P multivar. P
IPS 0.0036 0.0027
adj. gene predictor 0.1438 0.7199
E. Adj. gene predictor and IPS risk factors
Variable stand. estimate β significance P
Intercept −0.98 <0.0001
Sex (male) 0.55 <0.0001
Age ≥ 45 yrs 0.46 <0.0001
Table 1 (continued)
E. Adj. gene predictor and IPS risk factors
Variable stand. estimate β significance P
Leukocytes ≥ 15,000/ 0.66 <0.0001
Hb < 10.5 g/dL 0.52 <0.0001
Lymphocytes < 8% of WBC 0.39 0.0223
Albumin < 4 g/dL −0.07 0.4928
Stage IV −0.11 0.2328
Multiple linear regression of adjusted gene predictor on IPS factors, R2
= 0.22.
(A) Characteristics of high-risk and low-risk patients analyzed in this
study. (B) Cox regression of progression-free survival (PFS) on sex,
age and the adjusted gene predictor. (C) Cox regression of overall
survival (OS) on sex, age and the adjusted gene predictor. (D) Cox
regressions of PFS and OS on the IPS and the adjusted gene predictor.
(E) Multiple linear regression of the adjusted gene predictor on the
seven risk factors of the IPS.
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reduced (see also Supplementary methods, Supplementary
Table 1, Supplementary Fig. 4). This step was necessary since
the housekeeping genes in Vancouver and Kiel code sets
differed and thus the respective normalization. For re-cali-
bration, we used the same 23 genes of the published predictor
and used gene expression levels of the original training data
[2]. The adjusted gene predictor produced scores that corre-
lated strongly with the original scores in the previously
published Vancouver data set of both the training and the
validation cohort (Supplementary Figs. 5, 6, respectively).
The adjusted gene predictor compensated for the systematic
differences between data generated in Vancouver and Kiel,
yielding an excellent agreement between both data sets (R2=
0.99, Supplementary Fig. 3, right panel).
Based on the predictions of the previously published 23-
gene predictor [2], we separated our patient cohort into a
low- and high-risk group (Table 1A). Notable differences
occurred between both groups with respect to sex (male)
and age (≥45 yrs), with male and older patients over-
represented in the high-risk group. The adjusted gene pre-
dictor did not differentiate high-risk cHL patients with
respect to PFS (Fig. 1A, Cox model, p= 0.478), nor dif-
ferentiated two groups of different OS (Fig. 1B, Cox model,
p= 0.286) in BEACOPP-treated patients. In a multivariate
analysis including age (≥45 yrs) and sex, neither OS nor
PFS were significant (Cox model, OS: p= 0.299, PFS: p=
0.434). Higher age, but not male sex were significantly
associated with worse OS; low- or high-risk scores did not
further separate groups of patients with differential survival
(Fig. 1C, D). Age was the most important prognostic vari-
able for OS and PFS both in univariate and multivariate
analysis, whereas sex was prognostic for PFS exclusively
(Table 1B,C).
We next analyzed the role of the IPS, which consists of
the risk factors sex (male), age (≥45 yrs), leukocytes ≥
15,000/L, Hb < 10.5 g/dL, lymphocytes < 8% of WBC,
stage IV and albumin < 4 g/dL, in our 401-patient cohort.
We observed that the IPS was both significantly prognostic
for OS and PFS in BEACOPP-treated patients (Table 1D, p
= 0.0036 and p= 0.0027, respectively). The adjusted gene
predictor was significantly associated with the following
risk factors which are part of the IPS: sex, age, leukocytosis
and anemia at diagnosis (Table 1E). Consequently, the
adjusted gene predictor did not detect significant differences
for PFS and OS when adjusted for IPS in our cHL cohort
treated with BEACOPP-based regimens. Notably, the
adjusted gene predictor was associated with death from
acute toxicity (p= 0.022) and thus may rather describe
tolerability of BEACOPP chemotherapy and the overall
vulnerability of our patients.
We and others have recently shown that the cHL tumor
microenvironment can be utilized as a prognostic tool in
advanced stage cHL [5, 6]. Since in the context of
BEACOPP treatment the published 23-gene predictor was
not independently associated with outcome, we extended
our analysis to an additional set of 119 genes. These genes
were selected by involvement in Gene Ontology (GO)
biological pathways associated with immune response and
genes previously published to be associated with outcome
in cHL (Supplementary Table 2, see reference list and
selected GO terms in Supplementary Table 2). We tested for
the association of gene-expression levels with OS and PFS
by using Cox proportional hazard (PH) models on all
available 401 samples. Cox PH models were trained by
modelling each gene separately together with age, sex, and
IPS discretized into IPS ≤ 2 and IPS > 2. Thus, gene-wise p
values were adjusted for age, sex and IPS and corrected for
by multiple testing. None of the 119 genes tested were
associated with OS. Strikingly, however, PDGFRA,
TNFRSF8 (CD30) and CCL17 (TARC) were significantly
correlated with PFS (FDR < 0.05, Supplementary Table 3
for PFS, Supplementary Table 4 for OS). From a biological
perspective, all three identified genes play a prominent role
in cHL. TNFRSF8, also known as CD30, is typically
expressed on Hodgkin Reed-Sternberg cells (HRSC) [7].
CD30 further serves as a target for the FDA-approved
therapeutic brentuximab vedotin [7]. Moreover, platelet-
derived growth factor receptor A (PDGFRA) is a receptor
tyrosine kinase, and has also been shown to be expressed in
HRSC and not in normal B cells, indicating a role for
PDGFRA signaling in cHL pathogenesis [8]. Further, we
and others have shown, that high baseline serum CCL17
(TARC) levels, are related to poor response in cHL [9, 10].
In order to build a prediction model for PFS, we sepa-
rated our BEACOPP-treated cHL cohort into a training
(HD15, 210 patients) and an independent validation cohort
(HD12, 191 patients). The signature developed on the
training cohort (Supplementary Table 5) consisted of
CCL17 quantified relative to the four housekeeping genes.
Next, we established a cutoff to separate high- from low-
risk patients with corresponding KM curves shown in
Supplementary Fig. 7 (Cox model, p < 0.001). These labels
were also significantly associated with PFS in a multivariate
CoxPH model together with age (≥45 yrs) and sex (Cox
model, p < 0.001). We then applied our developed signature
to the validation cohort, where we utilized the cutoff
established on the training cohort to classify patients into
high- and low-risk. Importantly, high- and low-risk patients
significantly differed with respect to PFS (Supplementary
Fig. 8, Cox model, p= 0.0059). This finding could be
substantiated in a multivariate analysis together with age
(≥45 yrs) and sex (Cox model, p= 0.0040). To increase
statistical power, we combined HD12 and HD15 patients
for further model development. The corresponding PFS
model included CCL17, and additionally verified PDGFRA,
and TNFRSF8 for prognostication in our BEACOPP-treated
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cHL cohort. In line with our previous findings, this sig-
nature was prognostic for PFS (p < 0.001, Supplementary
Table 6). We note that this model needs to be validated in
independent cohorts in the future, while the former model
was developed on a training cohort (HD15) and confirmed
on an independent validation cohort (HD12).
In summary, the 23-gene predictor, which was pre-
viously shown to be a valuable prognostic tool in ABVD-
treated patients, was not prognostic in a multivariate ana-
lysis for PFS and OS in the context of BEACOPP-treated
advanced stage cHL. The most likely explanation is that the
more dose-intense BEACOPP treatment itself overcomes
the prognostic value of the gene predictor. In fact, the gene
predictor seems to exert its potential only in the context of
what it was originally designed for (ABVD-treated cHL)
and transferring it to a different clinical context failed also
in a previous attempt [11]. It is important to note, that the
gene predictor was designed to predict OS, which is influ-
enced by events not necessarily related to the aggressive-
ness of the lymphoma, such as death of other causes.
Moreover, differences in PFS do not necessarily translate
into differences in OS since effective therapy for relapsed
disease is available [12]. Thus, from a clinical perspective,
future biomarker development aiming at risk-stratification at
diagnosis might also need to be aligned to PFS and interim
PET/CT as an endpoint in cHL [13]. Moreover, different
therapeutic approaches including Brentuximab-Vedotin and
immune-checkpoint inhibition may generate the necessity to
develop diverse predictors for risk assessment in cHL. The
identification of PDGFRA, TNFRSF8 (CD30) and CCL17
(TARC) as single genes being prognostic for PFS after
multiple testing in the BEACOPP-treated patient cohort
highlights the potential of gene expression profiling for pre-
treatment risk assessment. Despite the fact, that these three
genes are likely mainly derived from HRSC, the abundance
of HRSC by image analysis did not show a significant
association with outcome in our previous study [5]. Since
quantification of large cells, such as HRSC and macro-
phages, is tricky by quantitative image analysis [5], the
relative cell content does not necessarily correlate with the
expression level of genes derived from these cell types. This
seems specifically true for secreted proteins as the ones
identified in our analysis. Future studies are required to
understand (i) how the number of HRSC and their potential
to secrete immunologically active proteins such as
PDGFRA, TNFRSF8 (CD30) and CCL17 (TARC) are
associated with each other, (ii) which features mediate the
aggressiveness of the disease under conventional che-
motherapy and (iii) how these features can be assessed to
identify patients suited for novel treatment strategies.
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Fig. 1 Kaplan–Meier survival
curves for the 23-gene
adjusted prognostic gene
predictor in 401 patients with
advanced stage cHL treated
within clinical trials HD12 and
HD15. A PFS comparing 23-
gene adjusted prognostic gene
predictor positive (red) and
negative (blue) cohorts. B OS
comparing 23-gene adjusted
prognostic gene predictor
positive (red) and negative
(blue) cohorts. C OS comparing
23-gene adjusted prognostic
gene predictor high-risk (red:
age < 45; green: age ≥ 45) and
low-risk (blue: age < 45; purple:
age ≥ 45) cohorts. D OS
comparing 23-gene adjusted
prognostic gene predictor high-
risk (red: female sex; green:
male sex) and negative (blue:
female sex; purple: male sex)
cohorts.
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